Published in Blood on February 26, 2010
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J Allergy Clin Immunol (2013) 1.01
Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet (2011) 0.97
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep (2014) 0.88
IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol (2014) 0.87
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods (2014) 0.87
Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia (2013) 0.87
Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics (2016) 0.86
Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. EBioMedicine (2016) 0.86
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods (2013) 0.84
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS One (2015) 0.84
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release (2013) 0.82
Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol (2016) 0.81
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. PLoS One (2013) 0.80
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunol Immunother (2013) 0.79
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) (2012) 0.79
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Interleukin-7 and interleukin-15 for cancer. J Cancer (2014) 0.78
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology (2016) 0.78
Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget (2015) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. Oncotarget (2016) 0.76
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A (2016) 0.76
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology (2017) 0.75
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology (2013) 0.75
The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent. Clin Cancer Res (2015) 0.75
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. J Cancer (2017) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol (2000) 12.81
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity (2009) 9.28
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest (2001) 4.37
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 3.23
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med (2001) 2.96
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Cytokines and T-cell homeostasis. Curr Opin Immunol (2007) 2.58
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (2008) 2.57
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol (2005) 2.44
Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther (2005) 2.31
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother (2005) 1.91
IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J Immunol (1998) 1.85
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther (2007) 1.62
The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol (1998) 1.60
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol (2004) 1.56
Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol (2000) 1.53
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther (2008) 1.38
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (2002) 1.36
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther (2009) 1.35
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol (2005) 1.26
Differential regulation of human IL-7 receptor alpha expression by IL-7 and TCR signaling. J Immunol (2008) 1.21
Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med (1991) 1.21
Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J Immunother (2006) 1.19
IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes. J Immunol (2007) 1.09
Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol (2007) 1.09
Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res (2008) 1.02
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother (2009) 0.89
IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol (2008) 0.88
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol (2009) 13.16
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A (2009) 2.86
CARs on track in the clinic. Mol Ther (2011) 2.86
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A (2010) 2.67
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol (2010) 2.43
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell (2011) 2.33
Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer (2003) 2.08
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med (2009) 1.98
T-cell therapy at the threshold. Nat Biotechnol (2012) 1.91
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood (2002) 1.89
Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood (2012) 1.87
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells (2010) 1.73
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther (2007) 1.62
Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol (2005) 1.54
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol (2012) 1.50
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res (2011) 1.48
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res (2003) 1.43
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med (2008) 1.35
A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res (2011) 1.33
Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood (2002) 1.29
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther (2003) 1.29
The ABCs of artificial antigen presentation. Nat Biotechnol (2004) 1.29
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol (2005) 1.28
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res (2012) 1.25
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A (2005) 1.24
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol (2008) 1.24
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One (2013) 1.19
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. J Clin Invest (2008) 1.16
Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol (2006) 1.16
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res (2013) 1.16
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res (2007) 1.15
The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther (2007) 1.13
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother (2011) 1.12
Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene (2002) 1.12
Hematopoietic stem cell engineering at a crossroads. Blood (2011) 1.10
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell Stem Cell (2012) 1.06
Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res (2002) 1.03
Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol (2006) 1.03
Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. Biol Blood Marrow Transplant (2012) 1.02
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood (2010) 1.01
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate (2009) 1.00
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med (2010) 1.00
Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nat Protoc (2011) 0.99
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood (2014) 0.97
A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol (2009) 0.97
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood (2003) 0.97
High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol (2013) 0.97
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest (2013) 0.96
Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. J Immunol (2004) 0.95
Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol (2009) 0.94
Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood (2007) 0.94
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging (2006) 0.94
Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem Cell (2010) 0.92
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother (2011) 0.90
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res (2005) 0.90
An in vivo platform for tumor biomarker assessment. PLoS One (2011) 0.89
Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol (2008) 0.88
Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure. PLoS One (2013) 0.87
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther (2008) 0.87
Animal models and molecular imaging tools to investigate lymph node metastases. J Mol Med (Berl) (2011) 0.87
Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J Immunother (2015) 0.85
Fetal gene therapy of alpha-thalassemia in a mouse model. Proc Natl Acad Sci U S A (2007) 0.85
Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization. J Immunol (2006) 0.84
Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther (2002) 0.83
Novel approaches to enhance the specificity and safety of engineered T cells. Cancer J (2014) 0.83
Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice. Stem Cells Int (2011) 0.82
Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Hum Gene Ther (2006) 0.81
Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nat Protoc (2011) 0.81
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (2013) 0.81
Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Hum Gene Ther (2009) 0.80
Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors. J Virol (2002) 0.80
Development of a new reporter gene system--dsRed/xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier. Mol Imaging (2003) 0.79
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Curr Hematol Rep (2004) 0.79
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. J Immunol Methods (2010) 0.79
Fulminant experimental autoimmune encephalo-myelitis induced by retrovirally mediated TCR gene transfer. Eur J Immunol (2005) 0.79
Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine (2007) 0.78